程序性死亡因子-1(PD-1)抑制药新药Nivolumab的临床研究进展  

Progress in Clinical Research on Novel PD-1 inhibitor Nivolumab

作　　者：杜玲玲[1] 徐佳骏[1] 

机构地区：[1]上海交通大学医学院附属仁济医院药剂科,上海200001

出　　处：《中国药师》2015年第11期1971-1974,共4页China Pharmacist

摘　　要：目的：介绍程序性死亡因子-1（PD-1）抑制药抗癌新药Nivolumab。方法：根据文献,对Nivolumab的作用机制以及目前获批或进入III期的几个主要适应证的临床研究结果进行综述与评价。结果： Nivolumab可通过与PD-1的结合,阻断其与关键配体PD-L1和PD-L2的相互作用,恢复T细胞的抗肿瘤活性；已经完成或正在进行中的多项临床研究结果显示Nivolumab单用或者与化疗药物或CTLA-4抑制药Ipilimumab合用,对于黑色素瘤、非小细胞肺癌以及肾细胞癌的效果优于目前临床应用的化疗药物,Nivolumab总体耐受性好,3-4级的不良事件主要为免疫介导肺炎,肝功能紊乱,疲劳等。结论： Nivolumab通过肿瘤免疫效应可改善对黑色素瘤、非小细胞肺癌以及肾细胞癌等多种肿瘤的治疗效果。Objective：To introduce a programmed death-1 （PD-1） inhibitor nivolumab used as a new antitumor agent. Methods：According to the literatures, the action mechanism of nivolumab and the clinical trial results on the main indications approved or being investigated in phase III trials were reviewed and evaluated. Results：Nivolumab could restore the antitumor activity of T cells through binding with PD-1 and consequently blocking its interaction with the key ligands of PD-L1 and PD-L2. Several completed and ongoing clinical trials showed that nivolumab used alone or combined with chemotherapy or CTLA-4 inhibitor ipilimumab exhibited better effica-cy when compared with current clinical used chemotherapy drugs in the treatment of melanoma, non-small cell lung cancer and renal cell carcinoma. Nivolumab was well tolerated during the treatment with such main grade 3-4 adverse events as immune-mediated pneu-monia, abnormal liver functions and fatigue. Conclusion：Through its anti-tumor immune response, nivolumab can improve the clinical efficacy in the treatment of various tumors including melanoma, non-small cell lung cancer and renal cell carcinoma.

关 键 词：程序性死亡因子-1 程序性死亡因子-L1 程序性死亡因子-L2 肿瘤免疫 黑色素瘤 非小细胞肺癌 肾细胞癌 

分 类 号：R079.1[医药卫生]